Published in Gene Therapy Weekly, March 22nd, 2007
The licence allows AMT to initiate the clinical development of AMT-020 to treat acute intermittent porphyria.
This follows successful collaboration between CIMA and AMT, demonstrating the safety and preclinical efficacy of the product, AMT-020. AMT-020 is an AAV vector gene therapy containing the porphobilinogen...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.